Eventide Asset Management LLC Has $12.22 Million Stock Holdings in Nektar Therapeutics (NASDAQ:NKTR)

Eventide Asset Management LLC grew its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 24.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,400,000 shares of the biopharmaceutical company’s stock after acquiring an additional 1,870,904 shares during the quarter. Eventide Asset Management LLC owned 0.05% of Nektar Therapeutics worth $12,220,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Victory Capital Management Inc. bought a new stake in Nektar Therapeutics in the 2nd quarter valued at $29,000. Valence8 US LP acquired a new stake in Nektar Therapeutics in the third quarter valued at about $34,000. Intech Investment Management LLC acquired a new stake in shares of Nektar Therapeutics during the third quarter valued at about $41,000. Values First Advisors Inc. acquired a new stake in shares of Nektar Therapeutics during the second quarter valued at about $56,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Nektar Therapeutics during the third quarter worth about $86,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Price Performance

Shares of NASDAQ:NKTR opened at $1.13 on Friday. Nektar Therapeutics has a 52-week low of $0.42 and a 52-week high of $1.93. The stock has a 50 day moving average price of $1.26 and a 200-day moving average price of $1.30.

Analyst Upgrades and Downgrades

NKTR has been the subject of several recent research reports. BTIG Research restated a “buy” rating and set a $4.00 price objective on shares of Nektar Therapeutics in a report on Monday, September 30th. Piper Sandler initiated coverage on Nektar Therapeutics in a research note on Monday, November 4th. They issued an “overweight” rating and a $7.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $3.50.

Nektar Therapeutics Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.